CHMX - SIGA Technologies drops 32% after FDA monkeypox update questions company antiviral

• SIGA Technologies ( NASDAQ: SIGA ) has dropped 32% in late Friday afternoon trading after a U.S. FDA monkeypox update stated that the company smallpox antiviral Tpoxx (tecovirimat) has not demonstrated efficacy or safety in human studies.
• Tpoxx is being made available to individuals who request it on a case-by-case basis through the Expanded Access program.
• "Conducting randomized, controlled trials to assess TPOXX’s safety and efficacy in humans with monkeypox infections is essential," the FDA said.
• Chimerix ( OTCPK:CHMX ), which markets the smallpox drug Tembexa (brincidofovir), is down 9% . Emergent BioSolutions ( EBS ), which has the smallpox vaccine ACAM2000, is down 4% .
• Bavarian Nordic ( OTCPK:BVNKF ), which produces the FDA-approved monkeypox vaccine Jynneos, is off ~5% .
• On July 27, the WHO said the worldwide number of monkeypox cases topped 19K .

For further details see: